NCNA - NuCana plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.40
+0.18 (+3.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.22
Open5.20
Bid0.00 x 2200
Ask5.95 x 1000
Day's Range5.20 - 5.45
52 Week Range4.01 - 19.28
Volume14,911
Avg. Volume49,154
Market Cap175.262M
Beta (5Y Monthly)3.05
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateFeb 17, 2020 - Feb 23, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,273.14
  • GlobeNewswire

    NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

    NuCana plc (NCNA) announced that the first patients have been dosed in its Phase III study of Acelarin (NUC-1031) plus cisplatin for the first-line treatment of patients with biliary tract cancer and that the study design is being presented at the ASCO-GI Conference in San Francisco. The enrollment of patients in NuTide:121 follows U.S. Food and Drug Administration (FDA) clearance of the company's investigational new drug application (IND) for Acelarin. “We are pleased to have commenced dosing the first patients in our Phase III NuTide:121 study,” said Hugh Griffith, NuCana’s Chief Executive Officer.

  • Innate Pharma's Filing for Leukemia Drug Accepted in Europe
    Zacks

    Innate Pharma's Filing for Leukemia Drug Accepted in Europe

    The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.

  • NuCana plc (NCNA): Are Hedge Funds Right About This Stock?
    Insider Monkey

    NuCana plc (NCNA): Are Hedge Funds Right About This Stock?

    Is NuCana plc (NASDAQ:NCNA) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting […]

  • New Strong Buy Stocks for December 11th
    Zacks

    New Strong Buy Stocks for December 11th

    New Strong Buy Stocks for December 11th

  • Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps
    Zacks

    Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps

    Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.

  • GlobeNewswire

    NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference

    NuCana plc (NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY on December 3rd and 4th, 2019. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • 3 “Strong Buy” Stocks Set for Triple Digit Gains
    TipRanks

    3 “Strong Buy” Stocks Set for Triple Digit Gains

    Which names can step up to the plate and hit the ball right out of the park? We are referring to the stocks that have a long growth runway ahead of them, lining up to deliver a win in the long-run. While these kinds of investments are highly sought after, it doesn’t mean they are easy to find.Luckily, TipRanks’ Stock Screener can help get the job done. The tool enabled us to filter our search by analyst consensus, price target and market cap as well as sort the results by upside potential from the current share price. As a result, we were able to identify 3 stocks primed for huge gains in the next twelve months.Huge isn’t an exaggeration as the stocks boast triple digit upside potential. If you thought it couldn’t get any better, guess again. Each of these stocks has garnered enough bullish recommendations from Wall Street analysts over the previous three months to earn a “Strong Buy” consensus rating.NuCana (NCNA)The clinical-stage biopharmaceutical company uses its innovative ProTide technology to try and improve treatment outcomes for patients with cancer. The technology has captivated the Street as it can transform widely-prescribed chemotherapy agents (nucleoside analogs) into safer and more effective therapies.While NuCana has found itself in hot water recently regarding the shift in priority for its Acelarin drug development, Piper Jaffray analyst Joseph Catanzaro tells investors not to forgot what the therapy’s implications could mean for NCNA shares. The company made the strategic decision to deprioritize the drug for ovarian cancer, and instead focus on its development as a first-line biliary tract cancer treatment.With NCNA recently getting the go-ahead from the FDA to start its Phase 3 study evaluating the efficacy of Acelarin in patients with biliary tract cancer, it’s no wonder Catanzaro is staying with the bulls. He does however note that he would like to see the biopharma bump up the development pace.To this end, the analyst lowered the price target from $25 to $15 to reflect that ovarian cancer can no longer be factored into his revenue model. Still, this target conveys his confidence in NCNA’s ability to soar 125% over the next twelve months. (To watch Catanzaro’s track record, click here)Like Catanzaro, the rest of the Street is betting on NCNA as a long-term winner. With 5 Buy ratings received in the last three months compared to no Holds or Sells, the consensus is unanimous: the biopharma is a ‘Strong Buy’. Adding to the good news, the $16 average price target implies 141% upside potential. (See NuCana stock analysis on TipRanks)Curaleaf (CURLF) Sure, Curaleaf is definitely beaten-down, but the cannabis company isn’t tapping out yet.Based in Massachusetts, Curaleaf already has interests in 19 states and 71 dispensaries currently being operated, with licenses to add 60 more. On top of this, Curaleaf stands to cement its status as a key player in the space thanks to its M&A activity. As the 30-day waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act has expired, it can proceed with its acquisition of the Select brand from Cura Partners Inc.Originally announced back in May, the purchase would give Curaleaf access to Select’s manufacturing, processing, distribution, marketing and retailing operations as well as all its adult-use and medical cannabis products under the Select brand name, including all intellectual property.GMP FirstEnergy’s Robert Fagan is one of the analysts that has been thoroughly impressed by the cannabis name: “We are generally encouraged by the rapid progress of the Select acquisition, representing a substantially quicker timeline than our current expectations for the Select acquisition to close during Q2/20. We are equally impressed with CURA’s ability to successfully amend the transaction terms on a fair basis for all parties, underpinning the company’s M&A expertise and providing CURA with downside protection while simultaneously incentivizing Select to maximize its performance.”With the current valuation reflecting an attractive entry point, Fagan's message is clear: now is the time to Buy. Attaching an $18 price target along with the rating, shares could skyrocket 214% in the coming twelve months. (To watch Fagan’s track record, click here)Similarly, other analysts are in CURLF’s corner. 4 Buys and 1 Hold assigned in the last three months add up to a ‘Strong Buy’ consensus. Its $12.78 average price target indicates 109% upside potential. (See Curaleaf stock analysis on TipRanks)SmileDirectClub (SDC)SmileDirectClub is giving consumers the confidence they need to keep on smiling, offering affordable teeth straightening aligners. While SDC’s performance following its September IPO has been rocky, several members of the Street say that the company’s strong long-term growth narrative should bring a smile to investors’ faces.In its first quarter as a publicly traded company, Jefferies analyst Brandon Couillard reminds investors that SDC actually posted a “solid beat”, with revenue reaching $180.2 million vs the $165.4 million estimate. Not to mention the company was able to ship 106,070 teeth aligners in the quarter, up from 72,387 in the prior-year quarter.Couillard adds that even though some thought the revenue guidance for the full year was somewhat underwhelming at $750 million to $755 million, these estimates are actually conservative in his view. “After a spate of headline noise, investor focus should pivot back to SmileDirectClub's strong underlying fundamentals, attractive valuation and reaccelerating Q4 growth,” he commented. Bearing this in mind, the five-star analyst reiterated his Buy rating as well as his $22 price target, suggesting 170% upside potential. (To watch Couillard’s track record, click here)Meanwhile, Stifel Nicolaus’ Jonathan Block argues that the stock is undervalued when you consider the large long-term opportunity for a $2,000 consumer clear aligner alternative. As a result, the five-star analyst maintains a bullish thesis. Based on the $19 price target, shares could climb 132% higher in the next twelve months.The rest of the Street is in agreement. As 10 Buys vs no Holds or Sells have been given in the previous three months, SDC is a ‘Strong Buy’. Its $21 average price target brings the upside potential to 134%. (See SmileDirectClub stock analysis on TipRanks)

  • Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
    Zacks

    Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

    Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.

  • GlobeNewswire

    NuCana to Present at the Jefferies 2019 London Healthcare Conference

    NuCana plc (NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 London Healthcare Conference in London, UK. The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

  • GlobeNewswire

    NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update

    NuCana plc (NCNA) announced financial results for the third quarter ended September 30, 2019 and provided an update on its extensive clinical program with its transformative ProTide™ therapeutics. As of September 30, 2019, NuCana had cash and cash equivalents of £58.1 million compared to £65.2 million as of June 30, 2019 and £77.0 million as of December 31, 2018. NuCana continues to advance its various clinical programs and reported a net loss of £3.9 million for the quarter ended September 30, 2019, as compared to £2.5 million for the quarter ended September 30, 2018.

  • GlobeNewswire

    NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON, Oct..

  • GlobeNewswire

    NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

    NuCana plc (NCNA) announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for its Phase III study (NuTide:121) of the investigational drug Acelarin in combination with cisplatin for patients with previously untreated locally advanced or metastatic biliary tract cancer. Mr. Griffith continued: “We believe our investigational drug product Acelarin in combination with cisplatin has the potential to significantly improve the survival outcomes of patients with advanced biliary tract cancer.

  • Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
    Zacks

    Lilly's Pancreatic Cancer Candidate Fails in Phase III Study

    Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.

  • Novavax Begins Phase III Study on Influenza Vaccine Candidate
    Zacks

    Novavax Begins Phase III Study on Influenza Vaccine Candidate

    Novavax (NVAX) starts a pivotal late-stage study on its pipeline candidate NanoFlu influenza vaccine in senior patients. Shares up.

  • What Percentage Of NuCana plc (NASDAQ:NCNA) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of NuCana plc (NASDAQ:NCNA) Shares Do Insiders Own?

    A look at the shareholders of NuCana plc (NASDAQ:NCNA) can tell us which group is most powerful. Generally speaking...

  • Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
    Zacks

    Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

    The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

  • Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
    Zacks

    Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study

    Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.

  • FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
    Zacks

    FDA Grants Orphan Drug Status to Acceleron's PAH Candidate

    The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.

  • NuCana plc (NCNA) Shares March Higher, Can It Continue?
    Zacks

    NuCana plc (NCNA) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in NuCana plc (NCNA).

  • Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why
    Zacks

    Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why

    Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.

  • Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease
    Zacks

    Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

    The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

  • GlobeNewswire

    NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    NuCana plc (NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire

    NuCana to Participate in Citi’s 14th Annual Biotech Conference

    NuCana plc (NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi’s 14th Annual Biotech Conference in Boston on September 5th, 2019. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire

    NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update

    Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, Aug. 21,.

  • NuCana Stops Patient Enrollment in Pancreatic Cancer Study
    Zacks

    NuCana Stops Patient Enrollment in Pancreatic Cancer Study

    NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.